ERBB2 and cancer: Compared to other subtypes, the patients with ER-positive and HER2-negative (defined as patients with HER2 0, 1+, or 2+ and a low ratio) cancers (approximately 70% of the population) are considerably less likely to achieve pCR but have the same improved outcome following pCR3,6.